We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+1.57%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
AUM
$1.92B
AUM Growth
+$129M
Cap. Flow
+$265M
Cap. Flow %
13.75%
Top 10 Hldgs %
49.82%
Holding
94
New
22
Increased
32
Reduced
16
Closed
13

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$85.9M
2
INCY icon
Incyte
INCY
+$75.6M
3
ARGX icon
argenx
ARGX
+$58.8M
4
INBX
Inhibrx, Inc. Common Stock
INBX
+$45.5M
5
PODD icon
Insulet
PODD
+$28.7M

Sector Composition

Rank Sector Weight
1 Healthcare 82.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ATXS
76
DELISTED
Astria Therapeutics
ATXS
$552K 0.03%
+60,692
New +$593K
PDSB icon
77
PDS Biotechnology
PDSB
$38.1M
$418K 0.02%
142,635
LUNG icon
78
Pulmonx
LUNG
$49.4M
$382K 0.02%
+60,246
New +$463K
KYTX icon
79
Kyverna Therapeutics
KYTX
$450M
$359K 0.02%
47,850
+37,850
+379% +$578K
GPCR icon
80
Structure Therapeutics
GPCR
$3.49B
$350K 0.02%
8,915
+182
+2% +$7.47K
MRNS
81
CALL
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$122K 0.01%
104,700
-750,000
-88% -$1.88M
ARGX icon
82
argenx
ARGX
$57.4B
-149,300
Closed -$58.8M
COO icon
83
Cooper Companies
COO
$13.7B
-21,236
Closed -$2.15M
INCY icon
84
Incyte
INCY
$23.5B
-1,327,178
Closed -$75.6M
INSM icon
85
CALL
Insmed
INSM
$23.2B
-100,000
Closed -$2.71M
MIRM icon
86
Mirum Pharmaceuticals
MIRM
$6.89B
-3,012
Closed -$75.7K
MRK icon
87
Merck
MRK
$324B
-651,299
Closed -$85.9M
NCNA
88
NuCana
NCNA
$5.37M
-680
Closed -$884K
SILK
89
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
-1,189,024
Closed -$21.8M
FUSN
90
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
-157,172
Closed -$3.35M
SWAV
91
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
-35,000
Closed -$11.4M
MRNS
92
PUT
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
-1,000,000
Closed -$9.04M
INBX
93
DELISTED
Inhibrx, Inc. Common Stock
INBX
-1,302,645
Closed -$45.5M

Similar funds

Sofinnova Investments's Q2 2024 Portfolio in Review

As of Q2 2024, Sofinnova Investments held 94 positions worth $1.92B, up 7.2% from $1.8B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Sofinnova Investments deployed $265M of net new capital in Q2 2024, opening 22 new positions and adding to 32 existing holdings. Its largest new stake was Stryker: 193,084 shares worth $65.7M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 94% a quarter earlier.

On the sell side, the largest reduction was Insulet, an estimated $28.7M trimmed.

  • Sofinnova Investments's largest Q2 2024 buy was Stryker: 193,084 shares worth $65.7M.
  • Sofinnova Investments added most to Align Technology in Q2 2024, an estimated $34.3M increase.
  • Sofinnova Investments's biggest Q2 2024 reduction was Insulet, cutting an estimated $28.7M.
  • Sofinnova Investments fully exited Merck in Q2 2024, selling an estimated $85.9M.
  • Sofinnova Investments's ten largest holdings make up 50% of its $1.92B portfolio in Q2 2024.
  • Sofinnova Investments opened 22 new positions and closed 13 in Q2 2024.
  • Sofinnova Investments's portfolio value rose 7.2% quarter-over-quarter to $1.92B.

Based on Sofinnova Investments's 13F filing for Q2 2024, filed 9 Aug 2024.